.svg){kind=small}
May-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
In May 2026, Stigma Grow concentrated its mix in Concentrates at 58.44% share with 31.48% year-over-year growth but a 9.96% month-over-month decline, while Capsules fell to 39.72% share with a 37.82% year-over-year contraction and a 5.09% month-over-month dip. Flower remained marginal at 1.84% share with a 25.82% month-over-month decline and an average price 107.4% above Concentrates, alongside a brand-wide 0.65% average price increase year over year; the net effect is a category tilt toward higher-velocity Concentrates offsetting but not fully counteracting Capsules’ contraction, implying the brand’s May 2026 revenue mix is more reliant on a single growth engine despite an overall year-over-year sales decline of 7.90%.
The shift raises positioning stakes: ranking 8th in Concentrates in Alberta places Stigma Grow within striking distance of higher-share rivals in that category while dealing with a 9.96% month-over-month pullback and a 5.09% month-over-month slide in Capsules, suggesting near-term gains depend on arresting monthly volatility in the lead category and stabilizing the secondary one. With Concentrates up 31.48% year over year but Capsules down 37.82% year over year, and the brand’s 24-month sales change at -37.58%, the pattern implies a narrow category-led strategy that supports share defense in Concentrates but caps multi-category reach unless Capsules’ decline is moderated or Flower’s 1.84% share is activated beyond its current 25.82% month-over-month fall.
Competitive Landscape
Stigma Grow sits at rank #8 in AB Concentrates in May 2026 after climbing 11 positions from #19 year over year, and improving 3 spots from #11 in February 2026 to match its peak rank of #8 in May 2026; by contrast, BoxHot moved from #2 to #1 with a 17.9% YoY sales increase while Endgame slipped from #1 to #2 amid a 31.2% YoY decline, and 3Saints jumped from #12 to #4 with 84.9% YoY growth. With Dab Bods holding #3 on 52.8% YoY growth and Nugz (Canada) advancing from #9 to #5 on 1.8% YoY growth, Stigma Grow’s ascent to #8 and new peak in May 2026 indicates a momentum phase where further single-digit rank gains are plausible if retention keeps pace with faster-rising mid-pack rivals.
Notable Products
Phoenix Tears Honey Oil (1g) posted the steepest move in May 2026 with a -57.6% month-over-month drop and slid to rank 6, while Phoenix Tears Resin (1g) also contracted by -10.2% and sat at rank 5. In contrast, CBD Softgels 15-Pack (750mg CBD) surged 129.8% MoM to rank 3, and Rippin Razz 2.0 Shatter (4g) jumped 111.3% MoM to rank 4, indicating that two rapid growers are climbing into the mid-pack as legacy concentrates retrench. With Phoenix Tears RSO (1g) still at rank 1 despite a -9.9% MoM decline and Concentrates occupying 4 of the top 6 slots, the mix implies reliance on the Phoenix Tears franchise is loosening as newer formats and Capsules absorb incremental demand.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
